Our client has a successful JAK inhibitor, “Product X”, which has large volumes of sales in the US; Product X sales are expected to continue to grow in the EU5, particularly through indication expansion.

As a third installment of our Aduhelm coverage, we look at the recently announced draft National Coverage Determination (NCD) by the Centers for Medicare and Medicaid Services (CMS).

Our client had a novel oral anticoagulant (NOAC) indicated for thromboembolic disorders on the market, which had seen significant commercial success and sales growth since its launch.

Our client had to make a business development decision regarding a potential new asset which would be developed in ulcerative colitis (UC) and atopic dermatitis (AtD).

Windrose Consulting Group collaborate with Cambridge University on a Executive education course on commercialisation strategy

Windrose Consulting Group are pleased to continue the New Year with two new Consultants joining our growing team. Muna Ali and Stacey McDonald

Windrose Consulting Group are pleased bring in the New Year with two new Analysts on our team and a promotion within the team.

Emerging Markets are not only influential in their own regions but represent a significant proportion of the world’s population and trade. They also represent a growing share of global healthcare spending. As such they offer an attractive growth prospect for the pharmaceutical industry.

December 1st is World AIDS Day and is an opportunity to reflect on pharmacological innovations that has turned a once fatal disease into a treatable condition. Infection rates have slowed in recent years due to increase in testing availability, as well as development of antiretroviral therapy and, more recently, pre-exposure prophylaxis (PrEP)

We are pleased to launch the first edition of our Windrose Consulting Group: Global News Roundup for Q1-Q3 2021.

In June, Windrose’s Elizaveta Tchebaniouk provided an analysis of Aduhelm’s approval in Alzheimer’s Disease (AD) and the dynamic environment surrounding Biogen’s launch in the US. High unmet need, uncertain evidence, modest clinical benefit, and affordability concerns continue to make for a highly complex commercial launch.

Download the report to find out how pricing and reimbursement decisions are made in the US, including, Payer Evaluation, Price setting and reimbursement

Download the report to find out about the French pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.

Windrose Consulting Group are pleased to welcome three new Analysts to our team.

Our client wanted to understand the non-muscle invasive bladder cancer (NMIBC) disease landscape, specifically for high-risk patients unresponsive to current non-surgical standard of care, for Germany, France, and Canada.

Windrose Consulting Group are pleased to announce the September promotions for our team.

Today on World Heart Day, Windrose would like to recognize all of the innovators, healthcare providers, and family caregivers who are striving to make the world a better place for those with cardiovascular diseases (CVD).

At Windrose, we have been celebrating over a year since having acquired Parioforma, a leader in value, access and price assessments in non-traditional markets. The acquisition has strengthened Windrose’s expertise in emerging markets, which has been a significant driver of growth in recent years.

Potential ripple effects for gene therapy access

Bluebird bio, one of the world’s earliest innovators in the gene therapy space, recently announced that they will move away from launching and operating in Europe as a company, driven primarily by misalignment around the value and prices of their rare disease portfolio.

Established in 1992, the Authorization for Temporary Use program in France (ATU) is among one of the oldest and most open early access programs in Europe.[1] It allows patients with rare or serious diseases access to drugs which are currently unauthorized in that indication. Although a complex process, it appeals to manufacturers, with recent funding for ATUs growing to over €1 billion a year.[2]